T 0215/20 of 19.01.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T021520.20230119
- Date of decision
- 19 January 2023
- Case number
- T 0215/20
- Petition for review of
- -
- Application number
- 15181545.3
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- Abstract on EPC2000 Art 056
- Application title
- (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL PROPYLENE GLYCOL SOLVATE AS SGT2 INHIBITOR FOR THE TREATMENT OF DIABETES
- Applicant name
- AstraZeneca AB
- Opponent name
- Generics (U.K.) Limited
- Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56
- Keywords
- Inventive step
- Catchword
- -
- Cited cases
- T 0777/08
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent in amended form with the following claims and a description to be adapted thereto: claims 1 to 5 of the main request, filed as auxiliary request 1 with the reply to the statement of grounds of appeal.